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Nocturnal oxygen enrichment underlie the resumption of breathing after apnoeic desaturations.
The occasional studies on the use of oxygen supplementation for OSA have generally used 100% oxygen supplementation and have yielded mixed results. Some findings suggest that oxygen therapy increases the incidence of apnoeas. 1 Other studies showed either an inappreciable effect 2, 3 or a degree of improvement due to a reduced frequency of apnoeas and hence less sleep fragmentation. 4, 5 The aim of the present study was to determine the effect of a modestly increased oxygen supplementation in patients with OSA. The reasoning for this was that such a modest increment in oxygen enrichment, although being less likely to lower appreciably the ventilatory chemostimulant drive, may nevertheless have some therapeutic value.
PATIENTS AND METHODS

PATIENTS
Five male patients, who had been diagnosed with OSA by an MESAM-4 ambulatory monitoring system, 6 were studied in a sleep laboratory of the Otolaryngology Clinic, Warsaw Medical University, Warsaw, Poland.
The patients were awaiting surgical intervention to relieve their persisting symptoms, since other treatments, such as continuous positive airway pressure, had failed. With the exception of hypoxaemia, none of them suffered any overt acute or chronic pulmonary, or other disease or used any medication at the time of the study.
All patients gave informed consent to enter the study.
STUDY PROTOCOL
The study protocol was approved by the Institutional Ethics Committee. The study was conducted on two consecutive 8-h nights. On the first night, the patients, who did not receive tranquilizers, slept in a normal atmosphere (control night), and on the second study night (oxygen-enriched night), patients breathed a mixture of 30% oxygen in nitrogen gas.
On both nights, the patients wore nasal prongs through which gas flowed only during the oxygen-enriched night at a rate of 4 l/min.
MEASUREMENT OF VENTILATORY AND CARDIAC PARAMETERS
The fractional concentration of end-tidal carbon dioxide (F ET CO 2 ) and breathing frequency (f) were measured at the nostrils using an infrared capnograph (Novametrix; Medical Systems, Inc., CT, USA). The capnograph was also used to detect the presence or absence of air movements, thus enabling the detection of apnoeic episodes. An apnoea was defined as a period of breathing cessation lasting ≥ 10 s.
Arterial oxygen saturation (SaO 2 ) and heart rate (HR) were determined by a fingerpulse oximeter (Accusat, Datascope Corp., NY, USA). All variables were recorded continuously and fed online into an IBM computer for data visualization and storage.
Arterial blood pressure was measured automatically every 15 min with a sphygmomanometer cuff wrapped around the left arm.
MOOD ASSESSMENTS
The patients' moods were self-assessed and documented on an analogue scale, according to the method of Bond and Lader, 7 1 h after awakening in the morning.
DATA ANALYSIS
For the control and oxygen-enriched nights, the percentage of sleeping-time spent on graded levels of SaO 2 , F ET CO 2 , f and the number of apnoeas was analysed. To evaluate the SaO 2 profile, the SaO 2 of each
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Nocturnal oxygen enrichment study night was stratified into a series of six graded levels, each successive level differing by 5% (≤ 74%, 75 -79%, 80 -84%, 85 -89%, 90 -94%, ≥ 95%).
A total apnoea index was calculated as a number of apnoeas per h. Apnoeas were stratified further into three groups of successive durations: 10 -19 s, 20 -29 s and ≥ 30 s. The apnoea index was also calculated for each group. To investigate whether or not the frequency of apnoeas depended on the nighttime oxygenation, we regressed the apnoea index (> 10 s) of each patient on his mean SaO 2 .
Results are expressed as means ± SE. Differences between the oxygen-enriched and control nights were tested for significance with a paired t-test; P < 0.05 was considered to indicate a statistically significant difference.
RESULTS
PATIENT DEMOGRAPHICS
Demographic details are summarized in Table 1 . The patients were eucapnic (F ET CO 2 x 100 < 4.5 for 80% of night). They showed incapacitating symptoms of hypersomnolence by day and loud snoring, restless sleep and abnormal chest breathing movements by night. These symptoms were confirmed by family members.
VENTILATORY PARAMETERS
ARTERIAL OXYGEN SATURATION MEASUREMENTS. The average SaO 2 increased from 89.4 ± 0.93% during the control night to 92.0 ± 1.1% during the oxygen-enriched night (P < 0.02). There were also appreciable changes in the SaO 2 profile. The percentage of time when high (≥ 95%) levels of SaO 2 were recorded was significantly (P < 0.05) higher during the oxygen-enriched night compared with control, and the time during which low levels of SaO 2 (75 -79%) were recorded was significantly (P < 0.05) lower ( Table 2 ). For the SaO 2 ≥ 95%, the increase was from 33 ± 7% of sleeping-time for the control night to 48 ± 9% of sleeping-time for the oxygenenriched night.
The lowest recorded SaO 2 associated with apnoeas was < 60% during the control night in all but one patient. This SaO 2 increased upon oxygen administration in all patients, on average, from 43.3 ± 8.1% to 48.5 ± 7.4% (P < 0.05). Table 3 ). The mean total apnoea index (> 10 s) decreased significantly by 24%. A smaller number of apnoeas in each subset of their duration contributed to the total decrease, but the incidence of the longest apnoeas, ≥ 30 s, decreased the most. Therefore, there was a relative shift towards the apnoeas of shorter duration within the smaller total number of apnoeas in the oxygen-enriched night. After regressing the apnoea index (> 10 s) of each patient on his mean SaO 2 , we observed a decrease in apnoea frequency with increasing mean SaO 2 in both control and oxygen-enriched nights. The respective decrease was 2.6 and 4.1 apnoeas/h/1% increment in SaO 2 . There were fewer 
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Nocturnal oxygen enrichment apnoeas for the same increase in SaO 2 in the oxygen-enriched night. However, the correlation coefficients for both relationships were insignificant, owing to interindividual variability in apnoea frequency.
OTHER VENTILATORY MEASUREMENTS.
There were inappreciable changes in both frequency of breathing and F ET CO 2 between the oxygen-enriched night and control (data not shown). In particular, no major trend for frequency decrease or hypercapnia, which would have implied a lower respiratory drive due to the oxygen enrichment used, was noted.
CARDIOVASCULAR PARAMETERS
Mean HR in each patient was lower in the oxygen-enriched night compared with control. The average decrease for all patients from control to oxygen-enrichment was from 78 ± 7 to 74 ± 7 beats/min (P < 0.05). Also, the maximum HR was lower and the minimum greater in the oxygen-enriched night compared with control. The average maximum/minimum gradient decreased from control to oxygen-enrichment (107 ± 29 to 73 ± 17 beats/min). This decrease did not assume significance due to a large scatter of data, but HR swings seemed to be less. Blood pressure also fell during the oxygenenriched night. On average, all blood pressure indices of interest that in the control night were: systolic, 128 ± 6 mmHg; diastolic, 82 ± 4 mmHg; mean = 99 ± 4 mmHg, maximum systolic, 198 ± 15 mmHg and diastolic, 150 ± 7 mmHg; and minimum systolic, 95 ± 6 mmHg and diastolic, 49 ± 4 mmHg decreased in the range of 4 -20% during the oxygen-enriched night. Only the diastolic pressure decrease to 75 ± 4 mmHg assumed significance, however (P < 0.05).
MOOD ASSESSMENT
The feeling of well-being, as rated on an analogue scale using the method of Bond and 
The effect of oxygen enrichment on the distribution of apnoeic (> 10 s) episodes/h during sleep. *P < 0.05.
DISCUSSION
This study suggests that a modest nocturnal oxygen enrichment in OSA patients, while not lowering ventilatory drive, improves arterial oxygen saturation and symptoms of OSA.
Previous experimental work has shown that an enhanced oxygen concentration, similar to that employed in the present study, albeit sufficient to affect SaO 2 , did not appreciably lower central respiratory drive, as assessed from the phrenic nerve activity in the rabbit. 8 Studies on oxygen therapy in OSA that employ a 100% oxygen supplementation have been inconclusive, however. Martin et al. 4 showed that both acute oxygen administration, for 30 min, and chronic administration, for 30 -90 days, reduced apnoeas and had beneficial cardiac effects. Gold et al. 9 showed that nocturnal administration of oxygen for one night caused a moderate reduction in apnoea frequency. This effect was sustained, but without further improvement, when followed by chronic oxygen administration. Others have found either no effect on 2,3 or worsening 1 of the apnoeic episodes on acute oxygen administration. However, the latter study 1 analysed the effects of intermittent, high-flow oxygen administration during just four consecutive apnoeic episodes, which throws some doubt on the interpretation. Although no serious untoward effects of oxygen have been documented, the therapy remains unproven.
The effect of increased oxygen concentration on the pathophysiology of OSA seems dichotomous. Oxygen may increase the incidence and duration of apnoeic episodes by interfering with the action of hypoxia and hypercapnia, which are the chemical stimuli that determine the breaking point of the apnoea. Oxygen weakens carotid body hypoxic ventilatory drive and also increases tolerance to carbon dioxide during apnoea. 10 Either is liable to delay apnoea termination. Carbon dioxide is considered the more important arousal stimulus, 2,9 because resumption of ventilation does not always require hypoxic levels of oxygen. On the other hand, chronic hypoxaemia, which is a feature of OSA, is known to inhibit the ventilatory chemosensory responses, 11 which would exacerbate the syndrome. By counteracting this inhibition, oxygen may reduce the incidence of apnoeic episodes.
Benefits conferred from oxygen may stem from its central action. Oxygen may relieve both central hypoxic ventilatory depression 12 and central hypoxic neuronal dysfunction. 13 The latter compromises motor output to pharyngeal muscles, which facilitates their collapse. Relief from the central hypoxaemic dysfunction may also be a factor in the improvement of well-being reported by the patients during the first hour after awakening, i.e. after oxygen discontinuation. Oxygen-sensitive metabolic pathways could be involved in this instance.
If OSA is regarded as an oscillating or periodic pattern of breathing, 14 oxygen could be beneficial by smoothing out breathing irregularity. In this model, ventilatory drive would be stabilized due to a decrease in the interapnoeic falls and the apnoeic dips in SaO 2 . Post-apnoeic hyperventilation and the consequent drop in the level of chemoexcitability would be less. Therefore, neural activation of upper airways is more apt to maintain them patent 15 and apnoea frequency reduced. In support of this line of reasoning, it has been shown that SaO 2 dips during sleep may underlie irregular et al.
Endovascular Embolization of Unruptured Vertebral Dissection
M Pokorski, U Jernajczyk
Nocturnal oxygen enrichment breathing, both at high altitude 16 and at sea level 17 in healthy persons, and in unhealthy infants, 18 and that oxygenation alleviates these irregularities.
The issue of oxygen supplementation is also important for the cardiovascular symptoms of OSA. HR changes, hypertension and dysrhythmias may all arise as a result of hypoxemia and self-perpetuate with progressing disease. 19 The upward shift in the lowest HR and the reduction in blood pressure observed in the present study, which are in accordance with the reflex cardiovascular effects of partial carotid chemosensory attenuation by oxygen, 20 would mitigate these symptoms.
A major limitation of the use of oxygen in OSA is that there are no markers that would allow prediction as to which patients would truly benefit from it. Martin et al. 4 have found that a positive acute response to oxygen is a good harbinger for a long-term response. These authors have also observed that relief from central hypoxic dysfunction persists after oxygen discontinuation. Gold et al. 9 have shown that the symptomatic improvement on acute oxygen persists, but does not result in further improvement upon chronic administration. In contrast to the findings of Martin et al., 4 the improvement was not observed to extend beyond the period of the administration. These divergent results may depend on various patient populations and complex mechanisms of oxygen action in ventilatory control.
In this study, we used a non-randomized approach with the 'control night' first to avoid carrying the effect of oxygen over to the control night. This was important because, as stated above, it is not known whether or not the effect of oxygen persists after the period of its administration. 4 In conclusion, although this study could not determine the mechanisms of oxygen action, we believe we have shown that a 9% nocturnal oxygen enrichment, while unlikely to lower ventilatory drive, may improve oxygen saturation, reduce apnoea frequency (particularly of the longest apnoeas) and stabilize the cardiovascular and psychological functions. Such an increment in oxygen enrichment seems to merit consideration for therapeutic trial, at least in otherwise untreatable patients, in the prevention of long apnoeic and desaturation episodes.
